Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5630-5635

  Rumi, Elisa ^a   Passamonti, Francesco ^a   Della Porta, Matteo G ^a   Elena, Chiara ^a   Arcaini, Luca ^a   Vanelli, Laura ^a   Del Curto, Cecilia ^a   Pietra, Daniela ^a   Boveri, Emanuela ^a   Pascutto, Cristiana ^a   Cazzola, Mario ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENETIC SUSCEPTIBILITY; HUMAN; KOLMOGOROV SMIRNOV TEST; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; THROMBOSIS;

ANTICIPATION, GENETIC; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PEDIGREE; PHENOTYPE; SURVIVAL RATE;

EID: 37049034302     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.6896     Document Type: Article

References (32)

1. Cario H, Goerttler PS, Steimle C, et al: The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 130:800-801, 2005
2. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al: Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108:346-352, 2006
3. Rumi E, Passamonti F, Pietra D, et al: JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 107:2206-2211, 2006
4. Pardanani A, Lasho T, McClure R, et al: Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood 107:4572-4573, 2006
5. Kralovics R, Stockton DW, Prchal JT: Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102:3793-3796, 2003
6. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
7. Passamonti F, Rumi E, Pungolino E, et al: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755-761, 2004
8. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
9. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
10. Berk PD, Goldberg JD, Donovan PB, et al: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132-143, 1986
11. Barosi G, Ambrosetti A, Finelli C, et al: The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 104:730-737, 1999
12. Murphy S, Iland H, Rosenthal D, et al: Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 23:177-182, 1986
13. Murphy S, Peterson P, Iland H, et al: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39, 1997
14. Passamonti F, Rumi E, Pietra D, et al: Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107:3676-3682, 2006
15. Brümmendorf TH, Holyoake TL, Rufer N, et al: Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95:1883-1890, 2000
16. Delhommeau F, Dupont S, Tonetti C, et al: Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109:71-77, 2007
17. Lu X, Levine R, Tong W, et al: Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102:18962-18967, 2005
18. Gangat N, Wolanskyj AP, McClure RF, et al: Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 21:270-276, 2007
19. Passamonti F, Rumi E, Arcaini L, et al: Leukemic transformation of polycythemia vera: A single center study of 23 patients. Cancer 104:1032-1036, 2005
20. Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, et al: Frequency and risk factors for thrombosis in idiopathic myelofibrosis: Analysis in a series of 155 patients from a single institution. Leukemia 20:55-60, 2006
21. Mesa RA, Li CY, Ketterling RP, et al: Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 105:973-977, 2005
22. Finazzi G, Caruso V, Marchioli R, et al: Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664-2670, 2005
23. Cervantes F, Alvarez-Larran A, Talarn C, et al: Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118:786-790, 2002
24. Lippert E, Boissinot M, Kralovics R, et al: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108:1865-1867, 2006
25. Moliterno AR, Williams DM, Rogers O, et al: Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108:3913-3915, 2006
26. Horwitz M, Goode EL, Jarvik GP: Anticipation in familial leukemia. Am J Hum Genet 59:990-998, 1996
27. Ranen NG, Stine OC, Abbott MH, et al: Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet 57:593-602, 1995
28. Deshpande HA, Hu XP, Marino P, et al: Anticipation in familial plasma cell dyscrasias. Br J Haematol 103:696-703, 1998
29. Yuille MR, Houlston RS, Catovsky D: Anticipation in familial chronic lymphocytic leukaemia. Leukemia 12:1696-1698, 1998
30. Vulliamy TJ, Marrone A, Knight SW, et al: Mutations in dyskeratosis congenita: Their impact on telomere length and the diversity of clinical presentation. Blood 107:2680-2685, 2006
31. Ferraris AM, Mangerini R, Pujic N, et al: High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood 105:2138-2140, 2005
32. Terasaki Y, Okumura H, Ohtake S, et al: Accelerated telomere length shortening in granulocytes: A diagnostic marker for myeloproliferative diseases. Exp Hematol 30:1399-1404, 2002